Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acorda Therapeutics

- PMLiVE

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Study will enrol patients who have ‘unmet clinical needs’ after receiving gene therapy

- PMLiVE

Pfizer/BioNTech vaccine shown to be effective against new COVID-19 variants

Vaccine tested against variants discovered in the UK and South Africa

- PMLiVE

Pfizer introduces new logo in a ‘shift from commerce to science’

First major rebranding in 70 years for pharma giant

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule

Recommendations made by the WHO's Strategic Advisory Group of Experts on Immunization

- PMLiVE

Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

Only those trial participants who are currently eligible under the EUA will be offered the vaccine

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

UPDATED: EU authorises Pfizer/BioNTech’s COVID-19 vaccine

Authorisation closely follows CHMP recommendation

- PMLiVE

Pfizer/BioNTech COVID-19 vaccine set for roll-out in Germany this month

Germany will begin vaccinating elderly in care homes on 27 December

- PMLiVE

EU fast-tracks review of Pfizer/BioNTech COVID-19 vaccine

CHMP meeting scheduled for 21 December

- PMLiVE

FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine

Formal approval in the US could follow 'within days'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links